Explore the unusual parallel between facilitating team collaboration to solve problems in fast-paced startups and role-playing games.

We explore the 505(b)2 pathway for expedited approval of previously-approved active drug ingredients with new formulations.

We discuss the role of the FDA in the drug approval process and their recent approval of the controversial Alzheimer's drug, Aduhelm.

We discuss three life science ideas that struggled on the market, but whose potential impact warrant a second look.

We discuss how approved drugs can fail on the market through a case examination of Exubera® and Aduhelm®.

We examine the three key archetypes and attributes of startup executives that are thrilling to work with and a privilege to work for.

We discuss how innovative life science startups can avoid fraud, following the conviction of Theranos founder & CEO, Elizabeth Holmes.

We break down 'Founder Fit' into three distinct phenomenon that influence your team's communication, dynamic, and funding.

We examine the aftermath and cost of Pfizer's major rebranding effort - and discuss where the pharmaceutical giant intends to go from here.